Compugen presents COM701 ovarian cancer trial poster at ESMO Jun 18, 2026 07:00AM
Compugen to present ovarian cancer trial data at ESMO congress Jun 11, 2026 07:00AM
H.C. Wainwright Reiterates Buy Rating on Compugen (CGEN) Jun 4, 2026 06:42AM
Compugen (CGEN) Misses Q1 EPS by 1c May 18, 2026 07:02AM
Lake Street Starts Compugen (CGEN) at Buy Apr 7, 2026 07:36AM


Mar 2, 2026 07:06AM Compugen (CGEN) Tops Q4 EPS by 68c
Jan 7, 2026 06:48AM H.C. Wainwright Starts Compugen (CGEN) at Buy
Dec 17, 2025 07:02AM Compugen monetizes royalties to AstraZeneca for up to $90 million
Nov 10, 2025 07:03AM Compugen (CGEN) Reports In-Line Q3 EPS
Aug 7, 2025 06:27AM Compugen (CGEN) PT Raised to $13 at Leerink Partners
Aug 6, 2025 07:01AM Compugen (CGEN) Misses Q2 EPS by 2c
May 19, 2025 07:01AM Compugen (CGEN) Misses Q1 EPS by 1c
May 13, 2025 07:04AM Compugen (CGEN) Announces Leadership Transitions Effective September 2025
Mar 4, 2025 10:26AM Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
Mar 4, 2025 07:02AM Compugen (CGEN) Misses Q4 EPS by 9c
Jan 13, 2025 06:02AM Oppenheimer Starts Compugen (CGEN) at Outperform
Nov 27, 2024 07:03AM Compugen (CGEN) Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Nov 12, 2024 07:04AM Compugen (CGEN) Tops Q3 EPS by 11c
Aug 6, 2024 07:05AM Compugen (CGEN) Tops Q2 EPS by 7c